{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T21:39:49Z","timestamp":1790199589685,"version":"4.1.0"},"reference-count":40,"publisher":"BMJ","issue":"4","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neurology, Neurosurgery & Psychiatry"],"published-print":{"date-parts":[[2014,4,1]]},"DOI":"10.1136\/jnnp-2013-305907","type":"journal-article","created":{"date-parts":[[2013,11,21]],"date-time":"2013-11-21T04:39:41Z","timestamp":1385008781000},"page":"419-430","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":58,"title":["Autocrine MMP-2\/9 secretion increases the BBB permeability in neuromyelitis optica"],"prefix":"10.1136","volume":"85","author":[{"given":"A.","family":"Tasaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Sano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Fujisawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Haruki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Koga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Kanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2013,11,20]]},"reference":[{"key":"key-10.1136\/jnnp-2013-305907-1","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1742-2094-10-8","article-title":"The history of neuromyelitis optica","volume":"10","author":"Jarius","year":"2013","journal-title":"J Neuroinflammation"},{"key":"key-10.1136\/jnnp-2013-305907-2","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis","volume":"264","author":"Lennon","year":"2004","journal-title":"Lancet"},{"key":"key-10.1136\/jnnp-2013-305907-3","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1212\/01.WNL.0000289761.64862.ce","article-title":"Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica","volume":"69","author":"Hinson","year":"2007","journal-title":"Neurology"},{"key":"key-10.1136\/jnnp-2013-305907-4","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/nrneurol.2010.72","article-title":"AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance","volume":"6","author":"Jarius","year":"2010","journal-title":"Nat Rev Neurol"},{"key":"key-10.1136\/jnnp-2013-305907-5","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1093\/brain\/awm047","article-title":"Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis","volume":"130","author":"Misu","year":"2007","journal-title":"Brain"},{"key":"key-10.1136\/jnnp-2013-305907-6","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1093\/brain\/awm062","article-title":"Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre","volume":"130","author":"Takahashi","year":"2007","journal-title":"Brain"},{"key":"key-10.1136\/jnnp-2013-305907-7","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1136\/jnnp-2012-302310","article-title":"Current concept of neuromyelitis optica (NMO) and NMO spectrum disorders","volume":"84","author":"Jacob","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"key-10.1136\/jnnp-2013-305907-8","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S1474-4422(12)70133-3","article-title":"Aquaporin 4 and neuromyelitis optica","volume":"11","author":"Papadopoulos","year":"2012","journal-title":"Lancet Neurol"},{"key":"key-10.1136\/jnnp-2013-305907-9","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s00401-010-0704-z","article-title":"Inflammation induced by innate immunity in the central nervous system leads to primary astrocyte dysfunction followed by demyelination","volume":"120","author":"Sharma","year":"2010","journal-title":"Acta Neuropathol"},{"key":"key-10.1136\/jnnp-2013-305907-10","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/ana.21837","article-title":"Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo","volume":"66","author":"Bradl","year":"2009","journal-title":"Ann Neurol"},{"key":"key-10.1136\/jnnp-2013-305907-11","doi-asserted-by":"crossref","first-page":"3072","DOI":"10.1093\/brain\/awn240","article-title":"Antibody to aquaporin-4 in the long-term course of neuromyelitis optica","volume":"131","author":"Jarius","year":"2008","journal-title":"Brain"},{"key":"key-10.1136\/jnnp-2013-305907-12","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1177\/1352458511424590","article-title":"Quantitative measurement of anti-aquaporin-4 antibodies by enzyme-linked immunosorbent assay using purified recombinant human aquaporin-4","volume":"18","author":"Kim","year":"2012","journal-title":"Mult Scler"},{"key":"key-10.1136\/jnnp-2013-305907-13","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1136\/jnnp-2012-304039","article-title":"CSF high-mobility group box 1 is associated with intrathecal inflammation and astrocytic damage in neuromyelitis optica","volume":"84","author":"Uzawa","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"key-10.1136\/jnnp-2013-305907-14","doi-asserted-by":"crossref","first-page":"5730","DOI":"10.4049\/jimmunol.181.8.5730","article-title":"Functional consequences of neuromyelitis optica-IgG astrocyte interactions on blood-brain barrier permeability and granulocyte recruitment","volume":"181","author":"Vincent","year":"2008","journal-title":"J Immunol"},{"key":"key-10.1136\/jnnp-2013-305907-15","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1136\/jnnp-2011-300434","article-title":"Sera from neuromyelitis optica patients disrupt the blood-brain barrier","volume":"83","author":"Shimizu","year":"2012","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"key-10.1136\/jnnp-2013-305907-16","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jneuroim.2011.04.009","article-title":"Increased serum matrix metalloproteinase-9 in neuromyelitis optica: implication of disruption of blood-brain barrier","volume":"236","author":"Hosokawa","year":"2011","journal-title":"J Neuroimmunol"},{"key":"key-10.1136\/jnnp-2013-305907-17","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1001\/archneurol.2011.148","article-title":"Markedly elevated soluble intercellular adhesion molecule 1, soluble vascular cell adhesion molecule 1 levels, and blood-brain barrier breakdown in neuromyelitis optica","volume":"68","author":"Uzawa","year":"2011","journal-title":"Arch Neurol"},{"key":"key-10.1136\/jnnp-2013-305907-18","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1093\/brain\/121.12.2327","article-title":"Matrix metalloproteinase-9 (gelatinase B) is selectively elevated in CSF during relapses and stable phases of multiple sclerosis","volume":"121","author":"Leppert","year":"1998","journal-title":"Brain"},{"key":"key-10.1136\/jnnp-2013-305907-19","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S0945-053X(97)90025-1","article-title":"Relating matrix metalloproteinase structure to function: why the \u201chemopexin\u201d domain?","volume":"15","author":"Murphy","year":"1997","journal-title":"Matrix Biol"},{"key":"key-10.1136\/jnnp-2013-305907-20","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1212\/01.wnl.0000216139.44259.74","article-title":"Revised diagnostic criteria for neuromyelitis optica","volume":"66","author":"Wingerchuk","year":"2006","journal-title":"Neurology"},{"key":"key-10.1136\/jnnp-2013-305907-21","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S1474-4422(07)70216-8","article-title":"The spectrum of neuromyelitis optica","volume":"6","author":"Wingerchuk","year":"2007","journal-title":"Lancet Neurol"},{"key":"key-10.1136\/jnnp-2013-305907-22","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria","volume":"69","author":"Polman","year":"2011","journal-title":"Ann Neurol"},{"key":"key-10.1136\/jnnp-2013-305907-23","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/jcp.22232","article-title":"Establishment of a new conditionally immortalized human brain microvascular endothelial cell line retaining an in vivo blood-brain barrier function","volume":"225","author":"Sano","year":"2010","journal-title":"J Cell Physiol"},{"key":"key-10.1136\/jnnp-2013-305907-24","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jns.2013.05.035","article-title":"NMO sera down-regulate AQP4 in human astrocyte and induce cytotoxicity independent of complement","volume":"331","author":"Haruki","year":"2013","journal-title":"J Neurol Sci"},{"key":"key-10.1136\/jnnp-2013-305907-25","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1247\/csf.11042","article-title":"Establishment and characterization of human peripheral nerve microvascular endothelial cell lines: a new in vitro blood-nerve barrier (BNB) model","volume":"37","author":"Abe","year":"2012","journal-title":"Cell Struct Funct"},{"key":"key-10.1136\/jnnp-2013-305907-26","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1136\/jnnp-2012-304306","article-title":"Blood-brain barrier destruction determines Fisher\/Bickerstaff clinical phenotypes: an in vitro study","volume":"84","author":"Saito","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"key-10.1136\/jnnp-2013-305907-27","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1016\/j.neurobiolaging.2013.01.012","article-title":"Advanced glycation end-products disrupt the blood-brain barrier by stimulating the release of transforming growth factor-\u03b2 by pericytes and vascular endothelial growth factor and matrix metalloproteinase-2 by endothelial cells in vitro","volume":"34","author":"Shimizu","year":"2013","journal-title":"Neurobiol Aging"},{"key":"key-10.1136\/jnnp-2013-305907-28","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/1742-2094-7-52","article-title":"Cerebrospinal fluid antibodies to aquaporin-4 in neuromyelitis optica and related disorders: frequency, origin, and diagnostic relevance","volume":"7","author":"Jarius","year":"2010","journal-title":"J Neuroinflammation"},{"key":"key-10.1136\/jnnp-2013-305907-29","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.bbrc.2010.02.157","article-title":"Anti-aquaporin-4 antibody induces astrocytic cytotoxicity in the absence of CNS antigen-specific T cells","volume":"394","author":"Kinoshita","year":"2010","journal-title":"Biochem Biophys Res Commun"},{"key":"key-10.1136\/jnnp-2013-305907-30","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/brain\/awp309","article-title":"Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice","volume":"133","author":"Saadoun","year":"2010","journal-title":"Brain"},{"key":"key-10.1136\/jnnp-2013-305907-31","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jns.2011.03.038","article-title":"Cerebrospinal fluid findings in aquaporin-4 antibody positive neuromyelitis optica: results from 211 lumbar punctures","volume":"306","author":"Jarius","year":"2011","journal-title":"J Neurol Sci"},{"key":"key-10.1136\/jnnp-2013-305907-32","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1172\/JCI117578","article-title":"Reversal of experimental autoimmune encephalomyelitis with a hydroxamate inhibitor of matrix metalloproteinases","volume":"94","author":"Gijbels","year":"1994","journal-title":"J Clin Invest"},{"key":"key-10.1136\/jnnp-2013-305907-33","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1016\/S0960-894X(03)00214-2","article-title":"Improved gelatinase a selectivity by novel zinc binding groups containing galardin derivatives","volume":"13","author":"Aug\u00e9","year":"2003","journal-title":"Bioorg Med Chem Lett"},{"key":"key-10.1136\/jnnp-2013-305907-34","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1759-1961.2010.009.x","article-title":"T cell migration into the central nervous system during health and disease: different molecular keys allow access to different central nervous system compartments","volume":"1","author":"Engelhardt","year":"2010","journal-title":"Clin Exp Neuroimmunol"},{"key":"key-10.1136\/jnnp-2013-305907-35","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/j.1600-065X.2012.01127.x","article-title":"Inflammatory cell trafficking across the blood-brain barrier: chemokine regulation and in vitro models","volume":"248","author":"Takeshita","year":"2012","journal-title":"Immunol Rev"},{"key":"key-10.1136\/jnnp-2013-305907-36","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1159\/000109933","article-title":"Natalizumab: targeting alpha4-integrins in multiple sclerosis","volume":"5","author":"Engelhardt","year":"2008","journal-title":"Neurodegener Dis"},{"key":"key-10.1136\/jnnp-2013-305907-37","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1212\/01.wnl.0000260064.77700.fd","article-title":"AFFIRM Investigators. MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS","volume":"68","author":"Miller","year":"2007","journal-title":"Neurology"},{"key":"key-10.1136\/jnnp-2013-305907-38","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1177\/1352458511421185","article-title":"Massive astrocyte destruction in neuromyelitis optica despite natalizumab therapy","volume":"18","author":"Barnett","year":"2012","journal-title":"Mult Scler"},{"key":"key-10.1136\/jnnp-2013-305907-39","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1001\/archneurol.2011.216","article-title":"Failure of natalizumab to prevent relapses in neuromyelitis optica","volume":"69","author":"Kleiter","year":"2012","journal-title":"Arch Neurol"},{"key":"key-10.1136\/jnnp-2013-305907-40","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1212\/WNL.0b013e31826845fe","article-title":"Does natalizumab therapy worsen neuromyelitis optica?","volume":"79","author":"Jacob","year":"2012","journal-title":"Neurology"}],"container-title":["Journal of Neurology, Neurosurgery & Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jnnp-2013-305907","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T17:52:56Z","timestamp":1601056376000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnnp.bmj.com\/lookup\/doi\/10.1136\/jnnp-2013-305907"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11,20]]},"references-count":40,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2014,3,5]]},"published-print":{"date-parts":[[2014,4,1]]}},"URL":"https:\/\/doi.org\/10.1136\/jnnp-2013-305907","relation":{},"ISSN":["0022-3050"],"issn-type":[{"value":"0022-3050","type":"print"}],"subject":[],"published":{"date-parts":[[2013,11,20]]}}}